LivaNova PLC

Item 8.01 Other Events. On December 6 and 7, 2023, executives of LivaNova PLC (the “Company”) will attend the Mizuho Medical Device & Healthcare Services Summit and Wolfe Research investor meetings. During these meetings, the Company expects to provide an update on operations with respect to the cybersecurity incident previously disclosed on November 20, 2023, as follows. The Company successfully executed a soft launch at its sites in the United States. These sites are now substantially operating at normal levels. In addition, the Company has begun executing a soft launch with respect to its manufacturing sites in Europe, though it may take longer for the Company’s European manufacturing sites to reach normal levels of operations compared to the Company’s U.S. sites. Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act. These statements include, but are not limited to, express or implied forward-looking statements relating to the Company’s expectations regarding its ability to re-launch and maintain operations at its manufacturing sites and the impact of the cybersecurity event on the Company’s business, results of operations, cash flows or financial condition. There are a number of risks, uncertainties and other important factors, many of which are beyond the Company’s control, that could cause the Company’s actual results to differ materially from the forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied include the ongoing assessment of the incident, including the Company’s potential discovery of additional informati